Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/08/2023 | 194.12% | Needham | → $3 | Reiterates | Buy → Buy |
| 09/07/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/07/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 08/04/2023 | 194.12% | Needham | → $3 | Reiterates | Buy → Buy |
| 08/01/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 08/01/2023 | 390.2% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 06/26/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/15/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/12/2023 | 194.12% | Needham | → $3 | Reiterates | Buy → Buy |
| 04/18/2023 | 194.12% | Needham | → $3 | Reiterates | → Buy |
| 03/24/2023 | 488.24% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/23/2023 | 488.24% | HC Wainwright & Co. | $6.5 → $6 | Maintains | Buy |
| 03/08/2023 | 390.2% | Cantor Fitzgerald | → $5 | Reiterates | → Overweight |
| 03/01/2023 | 537.25% | HC Wainwright & Co. | → $6.5 | Reiterates | → Buy |
| 01/25/2023 | 537.25% | HC Wainwright & Co. | $6 → $6.5 | Maintains | Buy |
| 05/12/2022 | 488.24% | HC Wainwright & Co. | $7.5 → $6 | Maintains | Buy |
| 09/22/2021 | 684.31% | Aegis Capital | $9 → $8 | Maintains | Buy |
| 09/22/2021 | — | WBB Securities | Upgrades | Buy → Strong Buy | |
| 03/04/2021 | 782.35% | Aegis Capital | → $9 | Initiates Coverage On | → Buy |
| 08/26/2020 | 390.2% | Citigroup | $6 → $5 | Maintains | Buy |
| 03/05/2020 | 488.24% | Needham | $10 → $6 | Maintains | Buy |
| 12/04/2019 | 512.75% | WBB Securities | → $6.25 | Upgrades | Speculative Buy → Buy |
| 09/04/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 06/06/2019 | 488.24% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 05/17/2019 | 96.08% | Wedbush | $7 → $2 | Downgrades | Outperform → Neutral |
| 03/01/2019 | 586.27% | Wedbush | $12 → $7 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/22/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 09/08/2023 | 194.12% | 李約瑟 | →$3 | 重申 | 購買→購買 |
| 09/07/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 08/07/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 08/04/2023 | 194.12% | 李約瑟 | →$3 | 重申 | 購買→購買 |
| 08/01/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 08/01/2023 | 390.2% | 康託·菲茨傑拉德 | →$5 | 重申 | 超重→超重 |
| 2023/06/26 | 488.24% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 2023年05月15日 | 488.24% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 2023年05月12日 | 194.12% | 李約瑟 | →$3 | 重申 | 購買→購買 |
| 04/18/2023 | 194.12% | 李約瑟 | →$3 | 重申 | →購買 |
| 03/24/2023 | 488.24% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 03/23/2023 | 488.24% | HC Wainwright公司 | $6.5→$6 | 維護 | 買 |
| 03/08/2023 | 390.2% | 康託·菲茨傑拉德 | →$5 | 重申 | →超重 |
| 03/01/2023 | 537.25% | HC Wainwright公司 | →$6.5 | 重申 | →購買 |
| 2023年1月25日 | 537.25% | HC Wainwright公司 | $6→$6.5 | 維護 | 買 |
| 2022年05月12日 | 488.24% | HC Wainwright公司 | $7.5→$6 | 維護 | 買 |
| 09/22/2021 | 684.31% | 宙斯盾資本 | $9→$8 | 維護 | 買 |
| 09/22/2021 | - | WBB證券 | 升級 | 購買→強買 | |
| 03/04/2021 | 782.35% | 宙斯盾資本 | →$9 | 開始承保 | →購買 |
| 2020/08/26 | 390.2% | 花旗集團 | $6→$5 | 維護 | 買 |
| 03/05/2020 | 488.24% | 李約瑟 | $10→$6 | 維護 | 買 |
| 2019/12/04 | 512.75% | WBB證券 | →$6.25 | 升級 | 投機性買入→買入 |
| 2019年09月04日 | - | 韋德布什 | 升級 | 中性→表現優異 | |
| 2019年06月06日 | 488.24% | 奧本海默 | →$6 | 開始承保 | →跑贏大盤 |
| 2019年05月17日 | 96.08% | 韋德布什 | $7→$2 | 評級下調 | 跑贏→中性 |
| 2019年03月01日 | 586.27% | 韋德布什 | $12→$7 | 維護 | 跑贏大盤 |
What is the target price for Cidara Therapeutics (CDTX)?
Cidara Treeutics(CDTX)的目標價格是多少？
The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by HC Wainwright & Co. on September 22, 2023. The analyst firm set a price target for $6.00 expecting CDTX to rise to within 12 months (a possible 488.24% upside). 16 analyst firms have reported ratings in the last year.
西達拉治療公司(納斯達克代碼：CDTX)的最新目標價是由HC Wainwright&Co.於2023年9月22日報道的。這家分析公司將目標價定為6美元，預計CDTX將在12個月內上漲至(可能上漲488.24%)。過去一年，有16家分析公司公佈了評級。
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
Cidara治療公司(CDTX)的最新分析師評級是多少？
The latest analyst rating for Cidara Therapeutics (NASDAQ: CDTX) was provided by HC Wainwright & Co., and Cidara Therapeutics reiterated their buy rating.
西達拉治療公司(納斯達克代碼：CDTX)的最新分析師評級由HC Wainwright&Co.提供，西達拉治療公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Cidara Treeutics(CDTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Cidara Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Cidara治療公司的最後一次評級是在2023年9月22日提交的，所以你應該預計下一次評級將在2024年9月22日左右的某個時候提供。
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
分析師對Cidara Treeutics(CDTX)的評級正確嗎？
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Cidara Therapeutics (CDTX) is trading at is $1.02, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Cidara治療公司(CDTX)評級被重申，目標價在0.00美元至6.00美元之間。Cidara Treateutics(CDTX)目前的交易價格為1.02美元，在分析師的預測範圍內。